| Characteristic . | MWOH (n = 94) . | MWH (n = 45) . | P Value . |
|---|---|---|---|
| Ethnicity | |||
| White, non-Hispanic | 76 (80.9) | 36 (80.0) | NA |
| White, Hispanic | 4 (4.26) | 1 (2.22) | NA |
| Black, non-Hispanic | 5 (5.32) | 4 (8.89) | NA |
| Black, Hispanic | 1 (1.06) | 1 (2.22) | NA |
| Asian/Pacific Islander | 1 (1.06) | 0 (0.0) | NA |
| Unknown | 7 (7.45) | 3 (6.67) | NA |
| Clinical characteristics, median (range) | |||
| Age, y | 67 (31–84) | 62 (36–86) | .345 |
| CD4 count, cells/μL | NA | 719.5 (253.0–1888) | NA |
| Nadir CD4 count, cells/μL | NA | 669 (253–1215) | NA |
| Viral load, copies/mL | NA | ≤20.0 (≤20.0–315) | NA |
| Time postvaccination, d | 104 (12–249) | 101 (4–253) | .704 |
| Anti-N IgG seropositivity | .267 | ||
| Anti-N IgG+ | 42 (44.7) | 15 (33.3) | |
| Anti-N IgG− | 52 (55.3) | 30 (66.7) | |
| Vaccine type received | .460 | ||
| mRNA-1273 | 42 (44.7) | 16 (35.6) | |
| BNT-162b2 | 52 (55.3) | 28 (62.2) |
| Characteristic . | MWOH (n = 94) . | MWH (n = 45) . | P Value . |
|---|---|---|---|
| Ethnicity | |||
| White, non-Hispanic | 76 (80.9) | 36 (80.0) | NA |
| White, Hispanic | 4 (4.26) | 1 (2.22) | NA |
| Black, non-Hispanic | 5 (5.32) | 4 (8.89) | NA |
| Black, Hispanic | 1 (1.06) | 1 (2.22) | NA |
| Asian/Pacific Islander | 1 (1.06) | 0 (0.0) | NA |
| Unknown | 7 (7.45) | 3 (6.67) | NA |
| Clinical characteristics, median (range) | |||
| Age, y | 67 (31–84) | 62 (36–86) | .345 |
| CD4 count, cells/μL | NA | 719.5 (253.0–1888) | NA |
| Nadir CD4 count, cells/μL | NA | 669 (253–1215) | NA |
| Viral load, copies/mL | NA | ≤20.0 (≤20.0–315) | NA |
| Time postvaccination, d | 104 (12–249) | 101 (4–253) | .704 |
| Anti-N IgG seropositivity | .267 | ||
| Anti-N IgG+ | 42 (44.7) | 15 (33.3) | |
| Anti-N IgG− | 52 (55.3) | 30 (66.7) | |
| Vaccine type received | .460 | ||
| mRNA-1273 | 42 (44.7) | 16 (35.6) | |
| BNT-162b2 | 52 (55.3) | 28 (62.2) |
Data are No. (%) except where indicated. Participants had received 2-dose vaccinated of either SARS-CoV-2 mRNA vaccine. Two-tailed Fisher Exact and Mann-Whitney U tests were used to compare between the groups. One participant had received heterologous mRNA vaccines and was excluded, and 43 MWH were used to determine nadir CD4 T cell count. Time postvaccination is the time between 2-dose immunization and sample collection.
Abbreviations: IgG, immunoglobulin G; MWH, men with HIV-1; MWOH, men without HIV-1; N, nucleocapsid.
| Characteristic . | MWOH (n = 94) . | MWH (n = 45) . | P Value . |
|---|---|---|---|
| Ethnicity | |||
| White, non-Hispanic | 76 (80.9) | 36 (80.0) | NA |
| White, Hispanic | 4 (4.26) | 1 (2.22) | NA |
| Black, non-Hispanic | 5 (5.32) | 4 (8.89) | NA |
| Black, Hispanic | 1 (1.06) | 1 (2.22) | NA |
| Asian/Pacific Islander | 1 (1.06) | 0 (0.0) | NA |
| Unknown | 7 (7.45) | 3 (6.67) | NA |
| Clinical characteristics, median (range) | |||
| Age, y | 67 (31–84) | 62 (36–86) | .345 |
| CD4 count, cells/μL | NA | 719.5 (253.0–1888) | NA |
| Nadir CD4 count, cells/μL | NA | 669 (253–1215) | NA |
| Viral load, copies/mL | NA | ≤20.0 (≤20.0–315) | NA |
| Time postvaccination, d | 104 (12–249) | 101 (4–253) | .704 |
| Anti-N IgG seropositivity | .267 | ||
| Anti-N IgG+ | 42 (44.7) | 15 (33.3) | |
| Anti-N IgG− | 52 (55.3) | 30 (66.7) | |
| Vaccine type received | .460 | ||
| mRNA-1273 | 42 (44.7) | 16 (35.6) | |
| BNT-162b2 | 52 (55.3) | 28 (62.2) |
| Characteristic . | MWOH (n = 94) . | MWH (n = 45) . | P Value . |
|---|---|---|---|
| Ethnicity | |||
| White, non-Hispanic | 76 (80.9) | 36 (80.0) | NA |
| White, Hispanic | 4 (4.26) | 1 (2.22) | NA |
| Black, non-Hispanic | 5 (5.32) | 4 (8.89) | NA |
| Black, Hispanic | 1 (1.06) | 1 (2.22) | NA |
| Asian/Pacific Islander | 1 (1.06) | 0 (0.0) | NA |
| Unknown | 7 (7.45) | 3 (6.67) | NA |
| Clinical characteristics, median (range) | |||
| Age, y | 67 (31–84) | 62 (36–86) | .345 |
| CD4 count, cells/μL | NA | 719.5 (253.0–1888) | NA |
| Nadir CD4 count, cells/μL | NA | 669 (253–1215) | NA |
| Viral load, copies/mL | NA | ≤20.0 (≤20.0–315) | NA |
| Time postvaccination, d | 104 (12–249) | 101 (4–253) | .704 |
| Anti-N IgG seropositivity | .267 | ||
| Anti-N IgG+ | 42 (44.7) | 15 (33.3) | |
| Anti-N IgG− | 52 (55.3) | 30 (66.7) | |
| Vaccine type received | .460 | ||
| mRNA-1273 | 42 (44.7) | 16 (35.6) | |
| BNT-162b2 | 52 (55.3) | 28 (62.2) |
Data are No. (%) except where indicated. Participants had received 2-dose vaccinated of either SARS-CoV-2 mRNA vaccine. Two-tailed Fisher Exact and Mann-Whitney U tests were used to compare between the groups. One participant had received heterologous mRNA vaccines and was excluded, and 43 MWH were used to determine nadir CD4 T cell count. Time postvaccination is the time between 2-dose immunization and sample collection.
Abbreviations: IgG, immunoglobulin G; MWH, men with HIV-1; MWOH, men without HIV-1; N, nucleocapsid.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
